Press release from Business Wire
Zoetis Appoints American Express Executive Vice President and General Counsel, Louise Parent, to its Board of Directors
Thursday, August 01, 2013
Zoetis Appoints American Express Executive Vice President and General Counsel, Louise Parent, to its Board of Directors16:40 EDT Thursday, August 01, 2013
FLORHAM PARK, N.J. (Business Wire) -- Zoetis Inc. (NYSE: ZTS), a former business unit of Pfizer Inc., today announced the appointment of Louise M. Parent, Executive Vice President and General Counsel of American Express Company, to its Board of Directors. Ms. Parent will serve on the Compensation Committee of the Board.
Ms. Parent has deep experience in corporate governance and board matters, gained during her tenure with American Express, where she works extensively with the Audit, Compensation, and Nomination and Governance committees in her role as General Counsel. Ms. Parent also has served on the operating committee and global management team of American Express for the last 10 years and as a member of the board of American Express Centurion Bank. She recently announced her retirement from American Express after a 36-year career with the global services company.
As a well-respected general counsel and leader at American Express, Ms. Parent brings perspectives that will be crucial as Zoetis becomes a fully independent company and further establishes its reputation as the world leader in animal health. She will provide the Zoetis Board with valuable global management and corporate governance experience based on her years supporting such efforts at American Express.
The Zoetis Board of Directors underwent additional changes recently to reflect its full independence from Pfizer, and is currently comprised of eight directors, including Ms. Parent.
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on a 60-year history as the animal health business of Pfizer, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, with a focus on both farm and companion animals. In 2012, the company generated annual revenues of $4.3 billion. With approximately 9,300 employees worldwide at the beginning of 2013, Zoetis has a local presence in approximately 70 countries, including 29 manufacturing facilities in 11 countries. Its products serve veterinarians, livestock producers and people who raise and care for farm and companion animals in 120 countries. For more information on the company, visit www.zoetis.com.
Forward-Looking Statements : This news release contains forward-looking statements, which reflect Zoetis' current views with respect to business plans or prospects, future operating or financial performance, and other future events. These statements are not guarantees of future performance. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2012, including in the sections thereof captioned “Forward-Looking Information and Factors That May Affect Future Results” and “Item 1A. Risk Factors”, in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov , www.zoetis.com , or on request from Zoetis.
Internet Posting of Information : We routinely post information that may be important to investors in the ‘Investors' section of our web site at www.zoetis.com , on our Facebook page at http://www.facebook.com/zoetis and on Twitter @zoetis. We encourage investors and potential investors to consult our website regularly and to follow us on Facebook and Twitter for important information about us.
Bill Price, 1-973-443-2742 (o)
Elinore White, 1-973-443-2835 (o)
Dina Fede, 1-973-443-2969 (o)
John O?Connor, 1-973-822-7088 (o)